Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 25

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 25
---
 that our current leadership structure is appropriate as it allows the Board to benefit from Dr. Rosen’s in-depth knowledge of our business in formulating and implementing strategic initiatives, provides a unified leadership to confront challenges facing our business, and enhances our ability to communicate our message and strategy clearly and consistently to stockholders. We will continue to periodically review our leadership structure and may make changes in the future if appropriate.

#### Role of the Board in Risk Oversight
One of the key functions of the Board is informed oversight of our risk management process. In particular, the Board is responsible for monitoring and assessing strategic risk exposure. Our executive officers are responsible for the day-to-day management of the material risks we face. The Board administers its oversight function directly as a whole, as well as through various standing committees that address risks inherent in their respective areas of oversight. Our Audit Committee oversees the management of risks associated with our financial reporting, accounting, auditing and cybersecurity matters; the Compensation Committee of the Board (the "Compensation Committee") oversees the management of risks associated with our compensation policies and programs; the Nominating and Corporate Governance Committee of the Board (the "Nominating and Corporate Governance Committee") oversees the management of risks associated with director independence, conflicts of interest, composition and organization of the Board and director succession planning; and the Science Committee of the Board (the "Science Committee") oversees the management of risks associated with our research and development strategy.

#### Meetings of The Board of Directors
The Board met eight times during the last fiscal year. As required under applicable NYSE listing standards, in fiscal year 2024, our independent directors met in regularly scheduled executive sessions at which only independent directors were present. All of our directors attended at least 75% of the aggregate number of meetings of the Board and committees on which they served, held during the portion of the last fiscal year for which they were directors or committee members, respectively.

Information Regarding Committees of the Board of Directors

During the year ended December 31, 2024, the Board had four standing committees: an Audit Committee, a Compensation Committee, a Nominating and Corporate Governance Committee and a Science Committee. The following

<div align='center'>12.</div>

table provides membership and meeting information for each of the committees during our 2024 fiscal year (Dr. Rosen and Ms. Mercier did not serve on any committees in 2024):

| Name                                   |     | Audit |     | Compensation |     |    Nominating 
 and Corporate 
    Governance |